-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

904.O3.6 904. Outcomes Research—Non-Malignant Conditions: Classical Hematology: From Horses to Zebras

Symposia: Outcomes Research—Non-Malignant Conditions Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, bleeding disorders, Anticoagulant Drugs, clinical trials, adult, Non-Biological therapies, Clinical Practice (Health Services and Quality), hemophilia, epidemiology, Clinical Research, health outcomes research, Combination therapy, Genetic Disorders, Diversity, Equity, and Inclusion (DEI) , thromboembolism, Diseases, thrombocytopenias, Immune Disorders, patient-reported outcomes, Therapies, Adverse Events, Pharmacology, survivorship, Surgical, Study Population, Human
Sunday, December 11, 2022: 9:30 AM-11:00 AM
295-296 (Ernest N. Morial Convention Center)
Moderators:
Ang Li, MD, MS, Baylor College of Medicine and Anna L Parks, MD, University of Utah
Disclosures:
No relevant conflicts of interest to declare.
This session will review treatment outcomes in rare hematologic conditions including aplastic anemia, thromobocytopenia and pyruvate kinase deficiency
9:30 AM

Aditya Jandial, MD, MBBS1*, Charanpreet Singh, MD, MBBS2*, Deepesh Lad, MD, DM3, Gaurav Prakash, MD, DM4,5*, Alka Khadwal, MD2*, Reena Das, MD2, Neelam Varma, MD6, Subhash Varma, MD2*, Pankaj Malhotra, MD2 and Arihant Jain, MD, DM7*

1PGIMER, PGIMER, CHANDIGARH, CHANDIGARH, India
2Postgraduate Institute of Medical Education and Research, Chandigarh, India
3Post graduate institute of medical education and research, CHANDIGARH, India
4Department of Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
5Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
6Hematology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
7Clinical Hematology and Medical Oncology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

9:45 AM

Kevin H.M. Kuo, MD, MSc, FRCPC1, Rachael F. Grace, MD2, Eduard J. van Beers, MD, PhD3*, Wilma Barcellini, MD4*, Andreas Glenthøj, MD, PhD5, Susanne Holzhauer, MD, MSc6*, Parija Patel, PharmD, MBA7*, Vanessa Beynon, MD7*, Junlong Li, PhD7*, Erin Zagadailov, PharmD, MS7* and Hanny Al-Samkari, MD8

1Division of Hematology, University of Toronto, Toronto, ON, Canada
2Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, MA
3Benign Hematology Center, Van Creveldkliniek, University Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands
4Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
5Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
6Department of Pediatric Hematology and Oncology, Charité University Medicine, Berlin, Germany
7Agios Pharmaceuticals, Inc., Cambridge, MA
8Division of Hematology/Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

10:00 AM

Olisaemeka Ogbue1, Waled Bahaj, MD2, Tariq Kewan, MD2*, Ramsha Ahmed, MD2*, Fauzia Ullah, MD2*, Valeria Visconte, PhD3, Sara Maskal4*, Carmelo Gurnari, MD2,5*, Steven Rosenblatt4* and Jaroslaw P. Maciejewski, MD, PhD, FACP2

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Rocky River, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Taussig Cancer Institute, Cleveland, OH
4Department of General Surgery, Cleveland Clinic, Cleveland, OH
5Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy

10:15 AM

Shannon M Reeves, BS, MS1*, Amanda J Llaneza, MPH2*, Sara K. Vesely, PhD, MPH3, Janna Journeycake, MD, MSCS4, Mohamad O. Khawandanah, MD5, Marshall Mazepa, MD6, Frank Akwaa, MD7*, Adam Cuker, MD, MS8, Shruti Chaturvedi, MBBS9, Neil Zakai10, Ming Yeong Lim, MBBChir11, Radhika Gangaraju, MD12, San Keller, PhD, MS13*, Spero Cataland, MD14 and Deirdra R Terrell, PhD15

1Univ of Oklahoma Health Sciences Ctr, Oklahoma City, OK
2University of Oklahoma Health Sciences Center, Oklahoma City, OK
3Biostatistics and Epidemiology, Hudson College of Public Health, The Univ. of OK Health Sciences Ctr., Oklahoma City, OK
4Jimmy Everest Center for Cancer and Blood Disorders, University of Oklahoma Health Sciences Center, Oklahoma City, OK
5Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
6Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN
7Wilmot Cancer Institute, Division of Hematology and Oncology, University of Rochester Medical Center, Rochester, NY
8Department of Medicine and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA
9Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD
10Division of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, VT
11Division of Hematology and Hematologic Malignancies, Department of Internal Medicine, University of Utah, Salt Lake City, UT
12Institute for Cancer Outcomes and Survivorship, University Of Alabama, Birmingham, AL
13American Institutes for Research, Chapel Hill, NC
14Division of Hematology, Department of Internal Medicine, Ohio State University Medical Center, Columbus, OH
15University of Oklahoma Health Sciences Ctr, Oklahoma City, OK

10:30 AM

Tzu-Fei Wang, MD, MPH1,2, Nicolas Grubic3,4*, Peter Tanuseputro, MD3,4,5,6* and Manish Sood, MD, MSc, FRCPC3,4,5*

1Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada
2Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada
3ICES, Toronto, ON, Canada
4Ottawa Hospital Research Institute, Ottawa, ON, Canada
5Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
6Bruyère Research Institute, Ottawa, ON, Canada

10:45 AM

Stacey Fedewa, PhD, MPH1*, Tyler W Buckner, MD, MSc2, Duc Q Tran Jr., MD, MSc3,4,5, Lorraine Cafuir, MD6, Ana G Antun, MD7, Shanna Mattis, MPH8* and Christine L Kempton, MD, MSc9

1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA
2University of Colorado, Aurora, CO
3Department of Hematology & Medical Oncology, Emory University School of Medicine, Atlanta, GA
4Emory University, Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Atlanta, GA
5Department of Hematology and Medical Oncology, Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, ATLANTA, GA
6Emory University Winship Cancer Institute, Atlanta, GA
7Emory University, Decatur, GA
8Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, GA
9Hemophilia of Georgia Center for Bleeding & Clotting Disorders of Emory, Emory University, Atlanta, GA

*signifies non-member of ASH